title: Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors.
abstract: According to a recent hypothesis, venous thrombosis results from the concurrence of several factors. This hypothesis was assessed in patients with portal or hepatic venous thrombosis by simultaneously investigating most of the currently identified prothrombotic disorders, local precipitating factors, and other risk factors such as oral contraceptive use. Patients with a tumorous obstruction and patients with cirrhosis with portal vein thrombosis were excluded. The prothrombotic disorders that were investigated included classical and occult myeloproliferative disorders; antiphospholipid syndrome; protein C; protein S and antithrombin deficiency; factor V Leiden; factor II; and methylene-tetrahydrofolate-reductase gene mutations. We found 1 or several prothrombotic disorders and a local precipitating factor in 26 and 10 of the 36 patients with portal vein thrombosis, respectively; and in 28 and none of the 32 patients with hepatic vein thrombosis, respectively. We found a combination of prothrombotic disorders in 5 and 9 patients with portal and hepatic vein thrombosis, respectively, whereas such a combination is expected in less than 1% of asymptomatic subjects. Of the 10 patients with a local precipitating factor, 8 had a prothrombotic disorder. Of the 13 patients who use oral contraceptives, 10 had a prothrombotic disorder. We conclude that portal or hepatic venous thrombosis should be regarded as an index for 1 or several prothrombotic disorders, whether or not local precipitating factors or oral contraceptive use are found. Concurrence of prothrombotic disorders is more common than expected. Extensive investigation of prothrombotic disorders and anticoagulation should be considered in patients with portal or hepatic venous thrombosis.
authors.affiliation: Laboratoire d'Hématologie et d'Immunologie, Hôpital Beaujon, Clichy, France.
authors.forename: M H
authors.initials: MH
authors.lastname: Denninger
authors.forename: Y
authors.initials: Y
authors.lastname: Chaït
authors.forename: N
authors.initials: N
authors.lastname: Casadevall
authors.forename: S
authors.initials: S
authors.lastname: Hillaire
authors.forename: M C
authors.initials: MC
authors.lastname: Guillin
authors.forename: A
authors.initials: A
authors.lastname: Bezeaud
authors.forename: S
authors.initials: S
authors.lastname: Erlinger
authors.forename: J
authors.initials: J
authors.lastname: Briere
authors.forename: D
authors.initials: D
authors.lastname: Valla
mesh_terms: D006502:Budd-Chiari Syndrome / Q000150:complications / Q000209:etiology* / Q000235:genetics; D005165:Factor V / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D011169:Portal Vein; D011247:Pregnancy; D011379:Prognosis; D011486:Protein C / Q000378:metabolism; D012307:Risk Factors; D020246:Venous Thrombosis / Q000150:complications / Q000209:etiology* / Q000235:genetics
chemical_list: D011486:Protein C; C095381:factor V Leiden; D005165:Factor V